In this file
Comparing alternatives to Rex MD is easier when you first identify what needs to change. The current Rex MD page names a branded Wegovy tablet offer. A fair comparison starts with that product, then makes it explicit when an alternative involves a different formulation rather than the same tablet at another price.
The provider’s current comparison point is: The current offer names branded Wegovy tablets rather than a generic oral category. The entries below offer different care and payment arrangements to examine against that point.
How to use this shortlist
CoreAge Rx is listed first under a commercial partnership. The first position is predetermined by that relationship, and links may earn compensation. It is not an independent finding that CoreAge has the safest medicine, the lowest total price, or the strongest patient outcomes.
Use Rex MD’s documented arrangement as the baseline, then test the alternatives against a branded tablet or a different treatment choice. We compare public care descriptions and payment terms. We have not purchased treatment, audited every professional license, or timed the support response. Use the linked source notes and obtain a current personal quote.
01. CoreAge Rx · sponsored first position
This is the paid featured reference for the question in this guide. Its placement does not establish that every feature discussed here is available through its program. Ask about the exact product and care access before assuming a match.
CoreAge Rx provides an online route to medical assessment and, where a clinician prescribes, pharmacy fulfillment. The service is our paid featured partner. That commercial relationship buys its prominent position here; it does not establish a better medicine, a better outcome, or suitability for any particular reader.
The sale offer shows starting equivalents of $99 for semaglutide and $149 for tirzepatide, without a separate membership charge. Its billing explanation uses a three-month example: $149 per month becomes a single $447 payment. A reader should obtain the duration and total for the selected prescription rather than assuming that the smaller figure is charged monthly.
A question to put to the provider: Can you send the full payment schedule and the name of my dispensing pharmacy before I accept the offer?
Read the CoreAge Rx provider file and cost explanation for the connected details.
02. Hello Alpha
The comparison point for Hello Alpha: Appointment-free care and pharmacy coverage are separate parts of the decision.
Hello Alpha describes a dedicated provider through appointment-free online visits and says it prescribes FDA-approved medicines. Its list includes products with different indications, which require individual clinical assessment.
Alpha Plus+ weight-care membership is advertised at $79 monthly. Prescription costs remain dependent on the product, pharmacy, and insurance. The care fee does not guarantee a prescription, covered drug, or refund after an authorization denial.
A question to put to the provider: Which medicine and indication would the clinician consider, and what would the pharmacy charge in addition to membership?
The Hello Alpha alternatives guide examines this arrangement in more detail. You can also consult the official provider page.
03. Maximus
The comparison point for Maximus: A 28-day supply and an annual offer need to be normalized before comparison.
Maximus lists compounded preparations alongside branded tablets and injections. Its page describes clinical supervision, but different product choices have different regulatory status and payment arrangements.
Compounded semaglutide is listed from $116 and tirzepatide from $198 per 28-day supply. A first-month discount is linked to a twelve-month purchase, and other page sections carry different ranges. Request the selected term’s full obligation and clinical fees.
A question to put to the provider: How many 28-day supplies and consultation charges are included in the full quoted term?
The Maximus alternatives guide examines this arrangement in more detail. You can also consult the official provider page.
04. Ro
The comparison point for Ro: A Body membership fee is additional to the medicine.
Ro’s Body program describes access to branded GLP-1 treatment and assistance with coverage. Clinical review, the program subscription, and prescription fulfillment are connected steps, but they are not necessarily charged by the same organization.
The listed Body offer is $39 for the first month, followed by $149 on the monthly arrangement. Annual prepayment can reduce the advertised monthly equivalent to $74. Medication is excluded from those membership figures and requires its own covered or cash-pay price.
A question to put to the provider: What will I pay for membership while insurance is being reviewed, and what is the total if the drug is not covered?
Read the Ro provider file and cost explanation for the connected details.
05. ZipHealth
The comparison point for ZipHealth: A clinical-service fee sits beside the advertised medicine amount.
ZipHealth’s weight-loss page describes branded medication options, including Wegovy and Zepbound. Patients arriving through a former Levity arrangement should verify the new support and contract details.
The program advertises starting medication figures from $149 per month plus a $79 clinical-service-and-support charge per treatment. The frequency of that extra fee and the exact pharmacy price need confirmation.
A question to put to the provider: How often is the $79 clinical charge collected, and does the new agreement replace any earlier Levity plan?
Use the official ZipHealth page to request the current plan and conditions.
06. Strut Health
The comparison point for Strut Health: The buccal lozenge and injectable semaglutide are different formulations.
Strut describes an online questionnaire, physician review, and automatic refills. Its lozenge contains vitamin B6 and is used inside the cheek; it should not be confused with a branded semaglutide tablet.
The page lists $129 for a monthly injectable vial and $199 for a thirty-day lozenge supply, with consultations and shipping included and final price determined after assessment. Compare the exact product and route, not just the ingredient name.
A question to put to the provider: What supports this specific formulation, and when must I act to stop the next automatic refill?
The Strut Health alternatives guide examines this arrangement in more detail. You can also consult the official provider page.
Your starting point: Rex MD
Rex MD’s weight-management page describes online assessment and a branded Wegovy tablet pathway involving NovoCare. The product is distinct from a compounded lozenge or a sublingual preparation.
The page advertises medication and provider care starting at $349 monthly and describes its listed titration strengths as covered by the offer. Confirm the exact branded product, eligibility, and later recurring amount.
Does the written quote cover this branded tablet and continuing clinical care at the prescribed strength?
Make the decision concrete
Bring these three checks to the shortlist. If an answer describes another product, a different payment period, or a service you are not eligible for, the comparison is not finished.
- Do not describe a compounded lozenge as a generic equivalent of the approved branded tablet.
- Request the named product, total initial payment, and next renewal in the same written quote.
- Confirm how the receiving clinician reviews existing treatment and how questions are handled between orders.
Separate the product from the provider
FDA approval belongs to a particular drug product, not to a review site’s list or a telehealth brand. A compounded preparation has not received that approval. Ingredient similarity does not establish the same route, formulation, manufacturing controls, or evidence.
Ask the clinician why the exact prescription fits your medical needs. Then ask the pharmacy for the label and instructions appropriate to that product. Read what compounding and FDA approval mean if those terms are being used interchangeably in a promotion.
Before accepting another offer
Keep the current agreement, prescription label, and any pending order information together. A new enrollment does not automatically stop the previous company’s next charge or authorize a continuation prescription.
Use the questions-before-purchase checklist to record the answers in your own words. A useful next step is a clear conversation and a complete proposal, not a decision based on a rank alone.
Source notes
Provider material describes the company’s own offer. Official medical references explain clinical and regulatory context; they do not endorse this publication or its commercial partner.
- CoreAge Rx: official treatment overview ↗Provider-published information · Checked September 22, 2026
- CoreAge Rx: current sale offer ↗Provider-published information · Checked September 22, 2026
- CoreAge Rx: plan billing explained ↗Provider-published information · Checked September 22, 2026
- CoreAge Rx: contact and professional-entity disclosures ↗Provider-published information · Checked September 22, 2026
- CoreAge Rx: purchasing process ↗Provider-published information · Checked September 22, 2026
- Hello Alpha: official program, pricing, and care details ↗Provider-published information · Checked September 22, 2026
- FDA: Wegovy semaglutide tablets, NDA 218316 approval letter ↗Regulatory source · Checked September 22, 2026
- Maximus: official program, pricing, and care details ↗Provider-published information · Checked September 22, 2026
- Weight Loss - Ro Body Membership | Ro ↗Provider-published information · Checked September 22, 2026
- Ro - Telehealth for ED, Hair loss, Skincare, Fertility and More ↗Provider-published information · Checked September 22, 2026
- ZipHealth: official program, pricing, and care details ↗Provider-published information · Checked September 22, 2026
- Strut Health: official program, pricing, and care details ↗Provider-published information · Checked September 22, 2026
- Rex MD: official program, pricing, and care details ↗Provider-published information · Checked September 22, 2026
- FDA: concerns with unapproved GLP-1 drugs ↗Regulatory / public agency · Checked September 22, 2026
- FDA: risks of compounded drugs ↗Regulatory / public agency · Checked September 22, 2026